IDT AUSTRALIA LIMITED — Capital/Financing Update 2023

Jun 8, 2023

==> picture [594 x 105] intentionally omitted <==

ASX ANNOUNCEMENT

9 June 2023

Retraction of Previous ASX Announcements

IDT Australia Limited (ASX: IDT) ( Company ) refers to its announcements dated 9 June 2023 lodged with the ASX under the titles “Tranche 1 Placement Completion”, “Application for quotation of securities” and “Cleansing Notice” ( Previous ASX Announcements ).

The Company wishes to retract the Previous ASX Announcements in full as Settlement and Allotment of Tranche 1 Placement Shares is now scheduled for Tuesday, 13 June 2023.

The Company will provide the ASX with updated confirmations once the Settlement and Allotment of Tranche 1 Placement Shares has been completed.

End

Authorised by the Chair of IDT Australia Limited.

For investor and media enquiries, please contact: Brendon Lau E: brendon@vantagepointpartners.com.au M: +61 409 341 613

About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT’s facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.